Table 3.
Correlation between preoperative D-Dimer concentration and clinicopathological characteristics in pancreatic ductal adenocarcinoma patients undergoing radical R0 resection, n (%)
| Characteristics |
Preoperative D-Dimer concentration
|
P value | |
|
> 0.53 mg/L (n = 117)
|
≤ 0.53 mg/L (n = 165)
|
||
| Age (yr) | 0.284 | ||
| > 60 | 65 (23.0) | 81 (28.7) | |
| ≤ 60 | 52 (18.4) | 84 (29.8) | |
| Sex | 0.260 | ||
| Male | 58 (20.6) | 93 (33.0) | |
| Female | 59 (20.9) | 72 (25.5) | |
| Blood type | 0.558 | ||
| A | 31 (11.0) | 56 (19.9) | |
| B | 40 (14.2) | 53 (18.8) | |
| AB | 9 (3.2) | 13 (4.6) | |
| O | 37 (13.1) | 43 (15.2) | |
| Diabetes | 0.871 | ||
| Absent | 84 (29.8) | 117 (41.5) | |
| Present | 33 (11.7) | 48 (17.0) | |
| Smoking status | 0.532 | ||
| Absent | 87 (30.9) | 128 (45.4) | |
| Present | 30 (10.6) | 37 (13.1) | |
| Alcohol consumption | 0.256 | ||
| Absent | 101 (35.8) | 134 (47.5) | |
| Present | 16 (5.7) | 31 (11.0) | |
| Family history of cancer | 0.785 | ||
| Absent | 112 (39.7) | 159 (56.4) | |
| Present | 5 (1.8) | 6 (2.1) | |
| Clinical symptoms | 0.845 | ||
| Absent | 23 (8.2) | 34 (12.1) | |
| Present | 94 (33.3) | 131 (46.5) | |
| Open surgery approach | 0.231 | ||
| Pancreaticoduodenectomy | 49 (17.4) | 81 (28.7) | |
| Distal pancreatectomy with splenectomy | 68 (24.1) | 84 (29.8) | |
| Tumor location | 0.231 | ||
| Head and neck | 49 (17.3) | 81 (28.7) | |
| Body and tail | 68 (24.1) | 84 (29.8) | |
| Degree of differentiation | 0.288 | ||
| Well | 18 (6.4) | 16 (5.7) | |
| Moderately | 85 (30.1) | 132 (46.8) | |
| Poorly | 14 (5.0) | 17 (6.0) | |
| Lymphovascular invasion | 0.742 | ||
| Absent | 83 (29.4) | 120 (42.6) | |
| Present | 34 (12.1) | 45 (16.0) | |
| Perineural invasion | 0.001 | ||
| Absent | 41 (14.5) | 29 (10.3) | |
| Present | 76 (27.0) | 136 (48.2) | |
| Capsular invasion | 0.831 | ||
| Absent | 21 (7.4) | 28 (9.9) | |
| Present | 96 (34.0) | 137 (48.6) | |
| Maximal tumor diameter (cm) | 0.027 | ||
| > 4 | 45 (16.0) | 43 (15.2) | |
| ≤ 4 | 72 (25.5) | 122 (43.3) | |
| T stage | 0.097 | ||
| T1 | 14 (5.0) | 20 (7.1) | |
| T2 | 58 (20.6) | 101 (35.8) | |
| T3 | 45 (16.0) | 44 (15.6) | |
| Lymph node metastasis | 0.769 | ||
| Absent | 68 (24.1) | 93 (33.0) | |
| Present | 49 (17.4) | 72 (25.5) | |
| N stage | 0.356 | ||
| N0 | 68 (24.1) | 93 (33.0) | |
| N1 | 34 (12.1) | 58 (20.6) | |
| N2 | 15 (5.3) | 14 (5.0) | |
| TNM stage | 0.608 | ||
| IA | 8 (2.8) | 12 (4.3) | |
| IB | 37 (13.1) | 55 (19.5) | |
| IIA | 23 (8.2) | 26 (9.2) | |
| IIB | 34 (12.1) | 58 (20.6) | |
| III | 15 (5.3) | 14 (5.0) | |
| Preoperative CA19-9 level (U/mL) | 0.056 | ||
| > 336.4 | 39 (13.8) | 38 (13.5) | |
| ≤ 336.4 | 78 (27.7) | 127 (45.0) | |
| Preoperative fibrinogen concentration (g/L) | 0.040 | ||
| > 3.31 | 67 (23.8) | 74 (26.2) | |
| ≤ 3.31 | 50 (17.7) | 91 (32.3) | |
| Adjuvant therapy | 0.268 | ||
| Absent | 56 (19.9) | 68 (24.1) | |
| Present | 61 (21.6) | 97 (34.4) | |